Go
View All
Reductions of olanzapine dose by up to 5 percentage points of D2 occupancy at each step, adjusted to allow use of quarter tablets
Re-initiation, after period of non-adherence to medication regime
Relapse after stopping medication
Relapse or Acute Exacerbation of Schizophrenia
Relational aspects of adherence
Relational aspects of prescribing practice
Relative adverse effects
Relative efficacy
Relative frequency sexual dysfunction (SD) with antidepressants
Relative infant dose
relative infant dose (RID), medication in breastfeeding mothers
Remedial treatments for psychotropic-induced sexual dysfunction
renal function, NSAIDs affecting sodium/lithium reabsorption
Renal impairment
Reported associations between antidepressants and increased prolactin
Response assessment
Restarting after a break in treatment
Restarting medication up to 2 weeks after stopping oral treatment
Restraint, exacerbating risks in drug-induced excited states
Restricted repetitive behaviours and interests, autism spectrum disorder
restricted repetitive behaviours and interests (RRBIs), core symptom of autism spectrum disorder
Reticulocyte count, psychotropic agent effects
Rilpivirine, psychiatric adverse reactions
Risk/extent of antipsychotic-induced weight gain (drugs in αbetical order)
Risk factors for orthostatic hypotension
Displaying items 31 - 60 of 72